Pacira BioSciences, Inc. - Common Stock (PCRX)

RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.

Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no earlier than 2039.

As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.

The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.

PACIRA BIOSCIENCES INC has a stellar value proposition. NASDAQ:PCRX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.

Consider PACIRA BIOSCIENCES INC as a top value stock. NASDAQ:PCRX shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.

PACIRA BIOSCIENCES INC (NASDAQ:PCRX), an undervalued stock with good fundamentals.

Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with promising study results.

Investors should take note ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock that remains attractively priced.